SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination

Gut. 2023 Jun;72(6):1227-1229. doi: 10.1136/gutjnl-2022-328169. Epub 2022 Jul 26.

Authors

Malte Benedikt Monin^{1

2}, Leona Baier³, Moritz Berger⁴, Jens Gabriel Gorny³, Taotao Zhou³, Robert Mahn³, Farsaneh Sadeghlar³, Christian Möhring³, Kathrin van Bremen^{3

2}, Christoph Boesecke^{3

2}, Jürgen Rockstroh^{3

2}, Christian Strassburg³, Anna-Maria Eis-Hübinger⁵, Maria Agnes Gonzalez-Carmona³

Affiliations

¹ Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany malte_benedikt.monin@ukbonn.de.
² German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany.
³ Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
⁴ Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
⁵ Institute of Virology, University Hospital Bonn, Bonn, Germany.

PMID: 35882561
DOI: 10.1136/gutjnl-2022-328169

No abstract available

Keywords: CHOLANGIOCARCINOMA; COVID-19; HEPATOBILIARY CANCER; HEPATOCELLULAR CARCINOMA; IMMUNE RESPONSE.

Publication types

Letter
Comment

MeSH terms

Antibodies, Viral
COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines
Antibodies, Viral